je.st
news
Tag: merck announces
Merck Announces Third-Quarter 2013 Financial Results
2013-10-28 12:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. 2013 Third-Quarter Non-GAAP EPS of $0.92, Excluding Certain Items; GAAP EPS of $0.38 Worldwide Sales were $11.0 Billion, a Decrease of 4 Percent Reflecting the Unfavorable Impact of Patent Expiries and a 2 Percent Negative Impact from Foreign Exchange Strong Growth in Vaccines and Immunology as well as ISENTRESS Breakthrough Therapy Designation Granted for MK-5172/MK-8742, in Development for the Treatment of Chronic Hepatitis C Virus Infection; V503, Mercks Investigational 9-valent HPV Vaccine has Completed Pivotal Phase III Study, on Track for 2013 Submission Narrows Full-Year Non-GAAP EPS Target to $3.48 to $3.52; GAAP EPS Target to $1.61 to $1.79 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2013. $ in millions, except EPS amounts ThirdQuarter2013 ThirdQuarter2012 Language: English Contact: MerckMedia Contacts:Kelley Dougherty, 908-423-4291Steven Cragle, 908-423-3461orInvestor Contacts:Carol Ferguson, 908-423-4465Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Merck Announces Global Initiative to Sharpen Commercial and R&D Focus
2013-10-01 13:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Company Redesigns Operating Model; Reduces Cost Base Initiative targets net reduction in annual operating expenses of approximately $2.5 billion by the end of 2015 Plan includes new workforce reductions of approximately 8,500 positions, in addition to pending, previously announced reductions Company reaffirmed 2013 full-year non-GAAP EPS target of $3.45 to $3.55; revised GAAP EPS range to $1.58 to $1.82 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a global initiative to sharpen its commercial and research and development (R&D) focus. The multi-year initiative will enable Merck to better target its resources behind those opportunities that have the potential to deliver the greatest return on investment, including bolstering its pipeline and implementing a more agile operating model, with a significantly reduced, more flexible cost structure. Language: English Contact: MerckMedia Contacts:Kelley Dougherty, 908-423-4291Steven Cragle, 908-423-3461orInvestor Contacts:Carol Ferguson, 908-423-4465Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: global
commercial
focus
initiative
Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment
2013-09-09 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational fertility treatment, corifollitropin alfa, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Merck is seeking FDA approval of corifollitropin alfa for Controlled Ovarian Stimulation (COS) in women participating in assisted reproductive technology. Language: English Contact: MerckMedia:Pam Eisele, 908-423-5042orTina Grasso, 267-893-9783orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
treatment
drug
acceptance
Merck Announces Second-Quarter 2013 Financial Results
2013-07-30 13:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. 2013 Second-Quarter Non-GAAP EPS of $0.84, Excluding Certain Items; GAAP EPS of $0.30 Worldwide Sales were $11.0 Billion, a Decrease of 11 Percent Reflecting the Unfavorable Impact of Patent Expiries and a 3 Percent Negative Impact from Foreign Exchange Partially Offset by Global Performance of Human Health Products Growth in Key Franchises Including Vaccines, Diabetes and Immunology Continued Return of Cash to Shareholders, Including $5 Billion Accelerated Share Repurchase Announced in May Reaffirmed Full-Year Non-GAAP EPS Target of $3.45 to $3.55, Excluding Certain Items; Revised GAAP EPS Range to $1.84 to $2.05 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2013. $ in millions, except EPS amounts SecondQuarter2013 SecondQuarter2012 Language: English Contact: Merck & Co., Inc.Media Contacts:Kelley Dougherty, 908-423-4291Steven Cragle, 908-423-3461orInvestor Contacts:Carol Ferguson, 908-423-4465Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Merck Announces Fourth-Quarter 2013 Dividend
2013-07-24 21:35:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.43 per share on the companys common stock for the fourth quarter of 2013. Payment will be made on Oct. 7, 2013, to stockholders of record at the close of business on Sept. 16, 2013. About Merck Language: English Contact: MerckMedia:Kelley P. Dougherty, 908-423-4291orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: announces
dividend
merck
announces fourthquarter
Sites : [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] next »